Patents Examined by Ardin H. Marschel
  • Patent number: 7452548
    Abstract: Novel compositions containing conjugated linoleic acids are efficacious as animal feed additives and human dietary supplements. Linoleic acid is converted to its conjugated forms in which the resulting composition is low in certain unusual isomers compared to conventional conjugated linoleic products.
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: November 18, 2008
    Assignee: Aker Biomarine ASA
    Inventors: Asgeir Saebo, Carl Skarie
  • Patent number: 7429378
    Abstract: The present invention relates to injecting a high affinity antagonist of MMPs into a diseased intervertebral disc.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: September 30, 2008
    Assignee: DePuy Spine, Inc.
    Inventors: Hassan Serhan, Thomas M. DiMauro, Mohamed Attawia, Sudhakar Kadiyala, David Urbahns, Scott Bruder, Laura J. Brown, Jeffrey C. Geesin
  • Patent number: 7425308
    Abstract: A system useful in performing active biological reactions includes an array of unit cells arranged in rows and columns. Row lines are coupled to row contacts of unit cells of the array. A row selector is coupled to the row lines to provide a row select voltage. Column lines are coupled to column contacts of the array. A column selector is coupled to the column lines to provide more than two column voltage states on the column lines. The unit cells are coupled to a supply and to an electrode, the row select and column select voltage states provides variable current output from the electrode of the unit cell. A return electrode is coupled to a potential and adapted to contact conductive solution including charged biological materials, wherein in the presence of the conductive solution, current is provided between various unit cells and the return electrode.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: September 16, 2008
    Assignee: Nanogen, Inc.
    Inventors: Donald E. Ackley, Scott O. Graham
  • Patent number: 7423063
    Abstract: Calcium salts, in particular calcium trifluoroacetate, are added to medicaments to provide cytotoxic and antitumoral activity. The medicaments can be administered to cancer patients as part of a method of treating a cancer patient. The medicaments can also be applied to a tumor to treat the tumor. The medicaments may be administered or applied orally or parenterally.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: September 9, 2008
    Assignee: Eureon AG
    Inventor: Alberto Bartorelli
  • Patent number: 7405227
    Abstract: Methods of treating ovarian cancer, endometrium cancer, cervical cancer, pancreatic cancer, bladder cancer, eve cancer, central nervous system cancer, thyroid cancer and lung cancer are disclosed. Specifically disclosed are methods of treating ovarian adenocarcinoma that has migrated into the abdominal cavity, a transitional cell carcinoma of the bladder, an epithelioid carcinoma in a pancreatic duct, an adenocarcinoma in a pancreatic duct, an adenocarcinoma in the cervical epithelium. The methods comprise administering to a patient a therapeutically effective amount of a compound of formula (Ia) wherein R1, R2, R3, R4, and R5 are described herein, wherein at least two of the five R1, R2, R3, R4, and R5 substituents are always hydrogen, at least one of the five substituents is always nitro, and at least one substituent positioned adjacent to a nitro is always iodo, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: July 29, 2008
    Assignee: BiPAr Sciences, Inc.
    Inventors: Ernest Kun, Jerome Mendeleyev, Carol Basbaurn, Hassan Lemjabbar-Alaoui, Valeria Ossovskaya
  • Patent number: 7393862
    Abstract: Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
    Type: Grant
    Filed: October 4, 2005
    Date of Patent: July 1, 2008
    Assignee: Celgene Corporation
    Inventor: Jerome B. Zeldis
  • Patent number: 7393869
    Abstract: Methods of using thiazolidine derivatives of formula (I) to treat cancer, inflammation, or other disorders related to the activities of protein phosphatases PTPN12 or PTPN2 in a mammal are disclosed.
    Type: Grant
    Filed: May 8, 2003
    Date of Patent: July 1, 2008
    Assignee: QLT Inc.
    Inventors: Zaihui Zhang, Timothy S. Daynard, Gabriel Bela Kalmar
  • Patent number: 7381546
    Abstract: The rapamycin gene cluster is an example of a gene cluster which includes a gene (rapL) leading to the formation of a precursor compound (pipecolic acid, in this case) which is required for inclusion in the larger product (rapamycin) produced by the enzymes encoded by the cluster. We have produced a mutant strain containing a rapamycin gene cluster in which the rapL gene is disabled. The strain does not naturally produce rapamycin but does so if fed with pipecolic acid. By feeding with alternative carboxylic acids we have produced variants of rapamycins. Tests have shown biological activity.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: June 3, 2008
    Assignee: Biotica Technology Limited
    Inventors: Peter Francis Leadlay, James Staunton, Lake Ee Khaw
  • Patent number: 7375137
    Abstract: The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: May 20, 2008
    Assignee: Merck HDAC Research, LLC
    Inventors: Nicholas G. Bacopoulos, Judy H. Chiao, Thomas A. Miller, Carolyn M. Paradise, Victoria M. Richon
  • Patent number: 7375124
    Abstract: The use is described of derivatives of ?-phenylthiocarboxylic and ?-phenyloxycarboxylic acids with formula (i): in which the substituents have the meanings described in the text, for the preparation of a medicine for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, its complications, the various forms of insulin resistance, and hyperlipidaemias
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: May 20, 2008
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Fabio Giannessi, Emanuela Tassoni, Maria Ornella Tinti, Pompeo Pessotto, Natalina Dell'Uomo, Anna Floriana Sciarroni, Tiziana Brunetti, Ferdinando Maria Milazzo
  • Patent number: 7371780
    Abstract: Calphostin C is used to treat subjects for cancer which is resistant to treatment by other forms of chemotherapeutic drugs, for example breast or uterine cancer, or other cancers characterized by tumor cells that have a defect in an apoptotic regulatory pathway which renders said cells resistant to at least some other forms of chemotherapeutic treatment. The other chemotherapeutic drug used with calphostin C is selected from the group comprising taxanes and anthracyclines, such as paclitaxel or doxorubicin. The use may take the form of administering calphostin C and then subjecting the patient to photodynamic therapy (PDT).
    Type: Grant
    Filed: October 27, 2004
    Date of Patent: May 13, 2008
    Inventor: Amadeo Parissenti
  • Patent number: 7371744
    Abstract: A phenothiazinium compound of Formula (I): wherein: A and B each independently is in which R? and R? each independently is a linear, branched or cyclic hydrocarbon group, or R? and R? together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring; and where XP? is a counteranion and P is 1, 2 or 3; except for the compounds in which A and B are both either —N(CH3)2 or —N(CH2CH3)2 for use in a treatment that requires removal, deactivation or killing of unwanted tissues or cells.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: May 13, 2008
    Assignee: Photopharmica Limited
    Inventors: Stanley B. Brown, Cassandra C. O'Grady, John Griffiths, Kirste J. Mellish, David I. Vernon
  • Patent number: 7365060
    Abstract: The present invention is related to a novel method for splitting nucleic acids at specific points on a complementary nucleic acid segment using a dinuclear copper-based compound of Formula I. Additionally, the present invention is related to a novel treatment of cancer, tumors, and cancer cells using a dinuclear copper-based compound of Formula I or a naked ligand of formula II: (Formula I and II).
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: April 29, 2008
    Assignee: University of Maryland
    Inventors: Steven E. Rokita, Kenneth D. Karlin, Kristi J. Humphreys, Lei Li, Narasimha N. Murthy
  • Patent number: 7361687
    Abstract: The present invention relates to novel arylsulphonamide compounds, defined by formula I and the description, as well as their method of preparation and their therapeutic use
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: April 22, 2008
    Assignee: Laboratoires Fournier SA
    Inventors: Martine Barth, Michel Bondoux, Pierre Dodey, Christine Massardier, Jean-Michel Luccarini
  • Patent number: 7361683
    Abstract: The present invention provides an injectable pharmaceutical composition containing, as an active ingredient, paclitaxel, an anti-cancer agent. The injectable pharmaceutical composition comprises an effective amount of paclitaxel, which is dissolved in polyoxyethylated castor oil, alcohol, and an injectable aqueous solution. A sufficient amount of CO2 is added to stabilize paclitaxel in the injectable pharmaceutical composition to make the injectable pharmaceutical composition to a pH about 5.0.
    Type: Grant
    Filed: November 24, 2004
    Date of Patent: April 22, 2008
    Assignee: Yung Shin Pharm. Ind., Co., Ltd
    Inventors: Fang-Yu Lee, Shan-Chiung Chen, Bin-Ken Chen, Chiung-Ju Tsai, Yuan-Ken Lin
  • Patent number: 7358222
    Abstract: Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.
    Type: Grant
    Filed: February 7, 2003
    Date of Patent: April 15, 2008
    Assignee: The Regents of the University of California
    Inventors: Jay A. Nadel, Kiyoshi Takeyama
  • Patent number: 7354948
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of a selective cytokine inhibitory drug. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Grant
    Filed: November 6, 2003
    Date of Patent: April 8, 2008
    Assignee: Celgene Corporation
    Inventor: Jerome B. Zeldis
  • Patent number: 7354954
    Abstract: According to the subject invention, there is disclosed a method for treating a patient/subject having a spastic disorder, a convulsive disorder, pain or epilepsy which includes administering to the subject having any one of these conditions a therapeutically effective amount of the compound gamma-aminobutyramide, analogs, substituted forms, derivatives, the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, or compounds which yield gamma-aminobutyramide as an intermediate, a metabolite, or a by-product.
    Type: Grant
    Filed: August 10, 2000
    Date of Patent: April 8, 2008
    Inventors: Jay M. Meythaler, Jean Peduzzi
  • Patent number: 7351723
    Abstract: Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: April 1, 2008
    Assignee: Nycomed GmbH
    Inventors: Rudolf Linder, Rango Dietrich
  • Patent number: 7348311
    Abstract: Dehydrodidemnin B with useful biological activity has formula (1).
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: March 25, 2008
    Assignee: Pharma Mar, S.A.
    Inventors: Kenneth L. Rinehart, Anna M. Lithgow-Bertelloni